Waters sees FY26 non-GAAP EPS $14.30-$14.50, consensus $14.32

The Company expects full-year 2026 organic constant currency revenue growth to be in the range of +5.5% to +7.0%. Including the positive impact of currency translation, full-year 2026 organic reported revenue is expected to be in the range of $3.355B to $3.405B, consensus $3.37B. The Company expects an acquired business contribution in full-year 2026 of approximately $3B to reported revenue on an owned-period basis. Including the positive impact of expected revenue synergies, total Company revenue for full-year 2026 is expected to be in the range of $6.405B to $6.455B on a reported basis. The Company expects full-year 2026 non-GAAP EPS to be in the range of $14.30 to $14.50, which includes $0.10 cents of accretion versus the Company’s standalone non-GAAP EPS profile due to our combination with the Biosciences and Diagnostic Solutions business of Becton, Dickinson & Company. This represents year-over-year non-GAAP EPS growth of approximately +8.9% to +10.4% for full-year 2026.